Barclays analyst Tom O’Malley raised the price target on Lam Research (NASDAQ: LRCX) to $275.00 (from $255.00) while maintaining an Equalweight rating.

“WFE raise of MSD% as total WFE for CY26 now expected to be >$140B (vs. $135B prior). Street was already at 30%+ product revenue and likely moves closer to 40%.

With CSBG “staying at these levels” for the rest of the CY according to company guidance, you get close to mid-teens growth, netting total company revenue in the low 30%s.

With the strength we are hearing in DRAM and F/L in the 2H, we would expect this moves even higher as the year goes along.

Advanced Packaging continues to become more significant and we estimate a run-rate of ~$2B with >50% Y/Y growth (vs. 40% prior).

The better stock action sets up the other Semi Cap names more favorably after what seemed to be a high bar and our only gripe with LRCX and the group remains valuation.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Tracking this call

Since this note+26% LRCX $265.55 → $333.89 (Oct 7) · target reached

This callScored on Oct 23, 2026, six months after the note: did LRCX reach $275?

Firm track recordBarclays reached 80% of its 40 scored targets within six months (#4 of 31 firms); on Lam Research, 2 of 3. Accuracy ranking →

Earnings reactionOne of 13 notes after Lam Research’s Apr 22 results: 11 of 13 raised targets. See every call →
Barclays on Lam Research · target history
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.